Recombinant polypeptides and methods of use thereof
AssigneeImunami Laboratories Pte. Ltd.
InventorsYa-Huei Chen, Ting-Long Lin
Life of this patent
Estimating the term…
Abstract
The present disclosure provides recombinant polypeptides, nucleic acids encoding the recombinant polypeptides and methods for using these polypeptides and/or nucleic acids in enhancing or inducing an immune response in a subject in need thereof. The present disclosure also provides methods of treating a cell proliferative disorder, such as cancer, by administering the disclosed polypeptides and/or nucleic acids to a subject in need thereof.
Claims27
A method of enhancing or inducing an immune response against a cancer cell in a subject in need thereof comprising administering to said subject a recombinant polypeptide comprising an amino acid sequence having at least 99% sequence identity to the polypeptide of SEQ ID NO:
- 1, or a nucleic acid encoding the recombinant polypeptide comprising an amino acid sequence having at least 99% 80% sequence identity to the polypeptide of SEQ ID NO:
- 1, wherein
- i. the recombinant polypeptide is acidic as determined by isoelectric point (pI);
- ii. the pI of the recombinant polypeptide is lower than the pI of SEQ ID NO:
- 1;
- and
- iii. aspartic acid, glutamic acid and leucine are each independently present in an amount greater than, or equal to, the amount of any other amino acid residue present within the recombinant polypeptide sequence.
(canceled)
(canceled)
(canceled)
A method of enhancing or inducing the endogenous presentation of disease associated antigens on the surface of a cancer cell in a subject in need thereof, comprising administering to said subject a recombinant polypeptide comprising an amino acid sequence having at least 99% sequence identity to the polypeptide of SEQ ID NO:
- 1, or a nucleic acid encoding the recombinant polypeptide comprising an amino acid sequence having at least 99% sequence identity to the polypeptide of SEQ ID NO:
- 1, wherein
- i. the recombinant polypeptide is acidic as determined by isoelectric point (pI);
- ii. the pI of the recombinant polypeptide is lower than the pI of SEQ ID NO:
- 1;
- and
- iii. aspartic acid, glutamic acid and leucine are each independently present in an amount greater than, or equal to, the amount of any other amino acid residue present within the recombinant polypeptide sequence.
(canceled)
(canceled)
(canceled)
A method of treating, preventing or alleviating at least one of the symptoms of cancer in a subject in need thereof comprising administering to said subject a recombinant polypeptide comprising an amino acid sequence having at least 99% sequence identity to the polypeptide of SEQ ID NO:
- 1, or a nucleic acid encoding the recombinant polypeptide comprising an amino acid sequence having at least 99% sequence identity to the polypeptide of SEQ ID NO:
- 1, wherein
- i. the recombinant polypeptide is acidic as determined by isoelectric point (pI);
- ii. the pI of the recombinant polypeptide is lower than the pI of SEQ ID NO:
- 1;
- and
- iii. aspartic acid, glutamic acid and leucine are each independently present in an amount greater than, or equal to, the amount of any other amino acid residue present within the recombinant polypeptide sequence.
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.